Source - SMW
ANGLE has announced that University Medical Centre Hamburg-Eppendorf has published new research detailing the use of ANGLE's Parsortix system in the prestigious peer-reviewed journal Clinical Chemistry. 

The paper is entitled 'Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells'.   The UKE cancer research team lead by Professor Klaus Pantel is a world-leading authority on the emerging field of liquid biopsy and, in 2015 alone, published 17 scientific papers in high ranking journals on different aspects of the application of liquid biopsy in cancer care. 

UKE compared the use of Parsortix with a leading antibody-based system, in parallel, using the same samples from both prostate and breast cancer patients. The Parsortix system allowed better downstream profiling of chemokines, as a result of substantially higher expression levels on the Parsortix harvested circulating tumour cells (CTCs).    Chemokines are proteins involved in the signalling between immune cells and cancer cells that are associated with the formation of metastasis and chemotherapy resistance. Therefore an understanding of the chemokine profile may play a key role in selection of drugs that will be effective for an individual patient.   The success of the Parsortix system in this application underpins its broader potential as a highly-effective cell capture and harvest system based on a combination of size and deformability.  

Unlike other commercially available systems, Parsortix is epitope-independent (not based on antibodies) so captures viable and undamaged CTCs, including the mesenchymal CTCs that are missed by other systems. Alternative ctDNA techniques cannot be used as the required analysis is of RNA.  


At 9:03am: (LON:AGL) Angle PLC share price was +1.5p at 72p



Related Charts

Angle (AGL)

0.00p (0.00%)
delayed 18:15PM